Skip to main content
SpringerLink
Log in

Tumorremission als prognostischer Marker in der Onkologie

Tumor remission as prognostic marker in oncology

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–1417. doi:10.1056/NEJMoa0805019

    Article  Google Scholar 

  2. Bokemeyer C, Bondarenko I, Hartmann JT et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:1535–1546. doi:10.1093/annonc/mdq632

    Article  CAS  PubMed  Google Scholar 

  3. Jain RK, Lee JJ, NG C et al. (2012) Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30:2684–2690

    Article  PubMed Central  PubMed  Google Scholar 

  4. Molina AM, Lin X, Korytowsky B et al. (2013) Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer 50:351:358

    Google Scholar 

  5. Louvet C, de Gramont A, Tournigand C et al. (2001) Correletion between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91:2033–2038

    Article  CAS  PubMed  Google Scholar 

  6. Choi, Charnsangarog, Faria et al. (2007) Correlation of computed tomography and positron emission in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759

    Article  PubMed  Google Scholar 

  7. Freireich EJ, Gehan EH, Sulman D et al. (1961) The effect on chemotherapy on acute leucemia in the human. J Chronic Diseases 14:593–608

    Article  CAS  Google Scholar 

  8. Albiges, Ondard, Negrier et al. (2007) Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 30:482–487

    Article  Google Scholar 

  9. Busch J, Seidel C, Goranova Iet al. (2014) Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer 50:563–569

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

C. Seidel gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Universitätsklinikum Hamburg-Eppendorf , Martinistraße 52, 20246, Hamburg, Deutschland

    C. Seidel

Authors
  1. C. Seidel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Seidel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seidel, C. Tumorremission als prognostischer Marker in der Onkologie. Onkologe 20, 487–489 (2014). https://doi.org/10.1007/s00761-014-2687-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-014-2687-1

Search

Navigation